Bavarian Nordic A/S announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment for the upcoming Marketing Authorisation Application (MAA) for CHIKV VLP, the Company's investigational chikungunya vaccine. The accelerated assessment, which is granted based upon CHMP's decision that the vaccine candidate is of major interest for public health and therapeutic innovation, may reduce the timeframe for the review of the MAA from 210 days under the standard review procedure to 150 days, not counting clock stops when applicants must provide additional information. In 2023, Bavarian Nordic successfully completed two Phase 3 studies of CHIKV VLP.

Both studies met their primary endpoints, demonstrating that CHIKV VLP induced high levels of neutralizing antibodies against chikungunya in individuals 12 years and above, with antibody titers equal to or above the threshold agreed with authorities as a marker of seroprotection. One study (NCT05072080) enrolled 3,254 healthy adults and adolescents aged 12 to 64 years of age, who were randomized to receive either a single intramuscular injection of CHIKV VLP, or placebo. The results up to day 22 post vaccination showed that CHIKV VLP was highly immunogenic, as demonstrated by the strong induction of chikungunya neutralizing antibodies in 98% of vaccinees in the active group.

Importantly, CHIKV VLP induced significant neutralizing antibodies in 47% and 97% of the subjects after 8 days and 15 days post vaccination respectively. These responses were robust and durable, as 86% of the subjects had seroprotective levels of neutralizing antibodies 6 months post vaccination. A similar study, which enrolled 413 healthy adults 65 years of age (NCT05349617), showed neutralizing antibodies in 87% of the vaccinees 22 days after a single vaccination.

Seroprotective antibodies were confirmed in 82% of the individuals at day 15. CHIKV VLP was well-tolerated across both studies and vaccine-related adverse events were mainly mild or moderate in nature.